Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma

Song, Huijuan; Huang, Pingsheng; Niu, Jinfeng; Shi, Gaona; Zhang, Chuangnian; Kong, Deling; Wang, Weiwei

doi:10.1016/j.biomaterials.2018.01.004

Cited by 139 publications

(127 citation statements)

References 39 publications

Supporting

Mentioning

126

Contrasting

Order By: Relevance

“…Similar to subunit nanovaccines, several groups have co‐encapsulated lysates of dissected tumor tissues and TLR agonists in particulate nanosystems to activate immune cells against cancer . Cancer‐derived membranes and CpG have been coloaded into PLGA nanoparticles to activate multi‐antigenic immunity and developed a productive approach to expedite endogenous immunity against autologous materials, which coincides with previous experiment results .…”

Section: Nanomaterials For Traditional and Novel Vaccine Deliverysupporting

confidence: 71%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid‐moving advances of nanoparticle‐based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.

show abstract

Section: Nanomaterials For Traditional and Novel Vaccine Deliverysupporting

confidence: 71%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

show abstract

“…Gels have demonstrated the propensity to target and deliver drugs to the lymphatic system when formulated properly. For example, one study examined a polypeptide hydrogel for immunotherapy in melanoma [181]. The hydrogel consisted of injectable self-assembled PEGylated poly(L-valine) and was formulated as a 3D porous hydrogel that had the ability to recruit dendritic cells.…”

Section: Other Methods Of Drug Delivery To the Lymphaticsmentioning

confidence: 99%

Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors

Cote

Rao

Alany

et al. 2019

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Although many solid tumors use the lymphatic system to metastasize, there are few treatment options that directly target cancer present in the lymphatic system, and those that do are highly invasive, uncomfortable, and/or have limitations. This review gives a brief overview of lymphatic function and anatomy, discusses changes that befall the lymphatics in cancer and the mechanisms by which these changes occur, and presents limitations for drug delivery to the lymphatic system. We then go on to summarize relevant techniques and new research for targeting cancer populations in the lymphatics and enhancing drug delivery intralymphatically, including intralymphatic injections, isolated limb perfusion, passive nano drug delivery systems, and actively targeted nanomedicine.

show abstract

“…DNA-based supramolecular hydrogels were reported to recruit and activate APCs by releasing a high concentration of CpG, which could serve as a promising method for tumor immunotherapy [193]. Song et al demonstrated a poly(L-valine) hydrogel for coencapsulating TCL, TLR3 agonist, poly(I:C) that realizes the controlled release of antigens and adjuvants, thus promoting antigen persistence and presentation to enhance the cytotoxic T-lymphocyte immune response against cancer [194]. A tumor-penetrable peptide-based hydrogel was prepared by encapsulating JQ-1 (a BRD4 inhibitor) and ICG coloaded tumor cells ( Fig.…”

Section: Novel Biomaterials For Cancer Immunotherapy Lipid-based Biommentioning

confidence: 99%

Advanced biomaterials for cancer immunotherapy

et al. 2020

View full text Add to dashboard Cite

Immunotherapy, as a powerful strategy for cancer treatment, has achieved tremendous efficacy in clinical trials. Despite these advancements, there is much to do in terms of enhancing therapeutic benefits and decreasing the side effects of cancer immunotherapy. Advanced nanobiomaterials, including liposomes, polymers, and silica, play a vital role in the codelivery of drugs and immunomodulators. These nanobiomaterial-based delivery systems could effectively promote antitumor immune responses and simultaneously reduce toxic adverse effects. Furthermore, nanobiomaterials may also combine with each other or with traditional drugs via different mechanisms, thus giving rise to more accurate and efficient tumor treatment. Here, an overview of the latest advancement in these nanobiomaterials used for cancer immunotherapy is given, describing outstanding systems, including lipid-based nanoparticles, polymer-based scaffolds or micelles, inorganic nanosystems, and others.

show abstract

Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma

Cited by 139 publications

References 39 publications

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors

Advanced biomaterials for cancer immunotherapy

Contact Info

Product

Resources

About